Between 2013 and 2018, the Takiwasi Center in Peru used the PPLUS information system to track patient profiles, treatments, and outcomes. Of 188 patients who left the therapeutic community, 45.2% (85) completed treatment and were discharged medically. Among the 54.8% who did not finish, 33.5% withdrew voluntarily, mostly during the first month. The center recorded 19,620 traditional Amazonian medicine practices: ayahuasca sessions made up 36.1% and purging sessions 39.1%. Research profiles showed 46.5% were psychology practitioners and 29.8% external researchers. PPLUS adoption was gradual and uneven, with peak records in 2016, but it shows potential as a research tool.
Ayahuasca is a psychotropic brew with serotonergic action, typically made from Banisteriopsis caapi and Psychotria viridis. This literature review examines its biochemical properties, the symptoms and signs it produces, and its use by Amazonian shamans and in homeopathic medicine. The review compares empirical shamanic indications with scientific studies from medicine, anthropology, and psychology to clarify the plant's utility in homeopathy. According to Fericgla, ayahuasca can induce curative, introspective, and therapeutic emotional and spiritual states. No psychological or physiological addiction has been observed from its consumption, and it poses no public health danger. Palma states that DMT is the main psychoactive agent, acting on the thymus and pineal gland.